Home > Boards > US Listed > Medical - Equipment > BrainsWay (BWAY)

BrainsWay Strengthens Senior Leadership Team with Appointment of

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 125
Posts 25,541
Boards Moderated 9
Alias Born 02/07/04
160x600 placeholder
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 6/3/2021 9:31:09 AM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 6/3/2021 9:29:07 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 6/2/2021 8:00:58 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 6/1/2021 8:01:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/24/2021 8:01:03 AM
Brainsway EPS misses by $0.03, beats on revenue Seeking Alpha - 5/20/2021 8:09:26 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/20/2021 8:01:04 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/5/2021 8:00:57 AM
Tender Offer Statement by Issuer (sc To-i) Edgar (US Regulatory) - 5/4/2021 9:29:32 AM
BrainsWay Announces Social Media Sweepstakes to Celebrate Mental Health Awareness Month GlobeNewswire Inc. - 5/4/2021 9:02:00 AM
BrainsWay launches noninvasive treatment for smoking addiction Seeking Alpha - 4/29/2021 9:10:50 AM
BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers GlobeNewswire Inc. - 4/29/2021 9:03:00 AM
RIOT, MARA, OCGN and MVIS among notable premarket gainers Seeking Alpha - 4/26/2021 8:21:35 AM
BrainsWay gets FDA clearance for Deep TMS protocol in major depressive disorder treatment Seeking Alpha - 4/26/2021 7:43:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/26/2021 7:30:54 AM
BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder GlobeNewswire Inc. - 4/26/2021 7:30:00 AM
BrainsWay Announces 100,000 Patients Treated with Deep Transcranial Magnetic Stimulation (Deep TMS) GlobeNewswire Inc. - 4/14/2021 9:03:00 AM
Brainsway EPS beats by $0.03, beats on revenue Seeking Alpha - 3/24/2021 4:24:50 PM
BrainsWay Ltd. Announces Closing of $45.2 Million Underwritten Public Offering of American Depositary Shares Including Full E... GlobeNewswire Inc. - 3/1/2021 7:00:00 AM
BrainsWay Ltd. Announces Pricing of $39,287,000 Underwritten Offering of American Depositary Shares GlobeNewswire Inc. - 2/23/2021 8:30:00 AM
BrainsWay readies ADS offering Seeking Alpha - 2/22/2021 4:06:39 PM
BrainsWay Ltd. Announces Proposed Public Offering of American Depositary Shares GlobeNewswire Inc. - 2/22/2021 4:02:00 PM
BrainsWay Enhances Commercial Leadership Team with the Addition of Fran Hackett as Vice President of North American Sales GlobeNewswire Inc. - 2/16/2021 7:30:00 AM
BrainsWay Reports Preliminary Record Fourth Quarter Revenue and Full-Year 2020 Financial Results GlobeNewswire Inc. - 2/16/2021 7:00:00 AM
BrainsWay Signs Exclusive Distribution Agreement with Gaelan Medical Trade LLC GlobeNewswire Inc. - 1/25/2021 8:00:00 AM
midastouch017   Thursday, 06/04/20 07:03:13 AM
Re: None
Post # of 29 
BrainsWay Strengthens Senior Leadership Team with Appointment of Christopher Boyer as Vice President of Global Marketing

GlobeNewswire GlobeNewswire•May 20, 2020

PATTERSON, N.J., May 20, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced the appointment of Christopher Boyer as Vice President of Global Marketing. Mr. Boyer will be responsible for worldwide marketing activities with a focus on expanding BrainsWay’s market share, leading the corporate go-to-market strategy, and overseeing the continued development of the BrainsWay brand. He has more than 15 years of medical device marketing and business development experience in both privately-held and multi-billion dollar publicly-held medical device companies.

“Chris is a seasoned marketing executive in the medical device industry, and we are pleased to welcome him to our senior leadership team,” said Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. “Chris has extensive experience leading and growing commercial organizations. We look forward to leveraging his significant experience as we seek to continue growing the demand for our Deep Transcranial Magnetic Stimulation (Deep TMS) system in major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).”

“I am excited for the opportunity to lead the marketing efforts for this emerging company,” said Mr. Boyer. “Deep TMS is a transformative technology with the potential to help a growing multitude of patients globally with significant unmet needs in a variety of mental health disorders, including MDD and OCD. I look forward to working with the BrainsWay team to expand the awareness and adoption of this novel therapy.”

Most recently, Mr. Boyer served as Managing Director of Drake Partners LLC, a start-up private equity and management consulting firm, where he led commercial activities for many of the portfolio companies. Prior to Drake Partners, he was Vice President at St. Jude Medical (now part of Abbott), where he managed the commercial integration of NeuroTherm, Inc. He was formerly the Vice President, America Sales and Global Marketing for NeuroTherm, an international pain management company, where he transformed the sales and marketing organizations to accelerate revenue growth. This effort contributed to the subsequent sale of the company to St. Jude Medical. Earlier in his career, Mr. Boyer held marketing roles of increasing responsibility at Smith & Nephew and Stryker. Prior to his medical device career, he was a field artillery captain in the United States Army and he received a Bronze Star Medal for his service. Mr. Boyer holds a B.S. in Mathematical Sciences from the United States Military Academy at West Point.

About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). BrainsWay is currently conducting and planning clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders.

https://finance.yahoo.com/news/brainsway-strengthens-senior-leadership-team-113010574.html


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences